Member Info for Diversified

Listening to a few interviews and reading a few articles last night. Israel, Columbia, Russia have all seen and will use IFN-B as a treatment for SARS-COV2 following successful trials/data.

We know from articles on here that IV is more potent/effective than injection and that nebulizer data is limited to date and also unavailable for most.

I’m excited

https://www.eltiempo.com/colombia/cali/nueva-polemica-por-uso-de-interferon-en-pacientes-con-covid-19-en-narino-522116

To translate the article they are saying that they are seeing positive results from trials using Interferon Beta.

Everything is now pointing towards a successful outcome here imo

It’s great to see luck and fortune. All the best with your future investments. Your patience has been rewarded.

But..... we will see you again after solidarity results

My buys were filled in the end but unreported.

I am surprised that the stock is difficult to purchase given the agreement they have with the lending facility but as you all know the stock has a tendency to spike on good news.

It’s apparent that the stock is going into a news rich period and that the share price which imo is significantly undervalued, will rerate on the next few weeks.

Looking forward, to next week.

Actively trying to buy stock with NT.

Getting angry watching mm drop Price knowing there is no stock

https://www.pscp.tv/w/celCQjFkdktPVmtyTE9vUVh8MURYeHlBWm1keld4TU8FGfSi7OllaAFmiOwLYT3Cc1C79A7a2QerW39fZ6hs?t=2m40s

Expecting initial results within the next 3/4 months:

https://youtu.be/j5nOmHlwpr0

7 minutes 30 seconds.

This could mean we will get initial results for T are imminent, correct me if I have missed something.

- REMAP results imminent
- WHO results imminent
- MARTINS update imminent

Good post sax.

https://youtu.be/86_uTpZclik

Interferon beta is a massive buzz word right now that will hopefully pick up with global recognition through the WHO trials for Traumakine.

It’s beyond comprehension how the share price would react to successful trails. Exposure, risk v reward that I’m more than happy with.

Out of interest, has anyone experienced difficulties buying this stock?

As sad as I am, I’m still waiting to watch the WHO press conference to start!

Do you think the results will be announced by WHO for FARN to then release an intraday statement, or that the news will be released by FARN prior to WHO addressing the globe?

Or today ;-)

WHO solidarity results imminent, massive upside for this tightly held stock.

I found it of interest that the WHO dropped certain treatments just recently but not interferon which can only be seen as a positive imo.

With SNG giving substance to the effectiveness of interferon the proposition has been derisked imo.

Every shareholder currently invested is of the opinion that this is a BUY or at least HOLD otherwise they would be selling into the current liquidity.

Many catalysts in the near term. What I like about the current pipeline is that any one of their treatments are company makers. I have only recently built a position but find the current risk v reward very compelling.

ICU treatment in Farons case may well be subject to less treatments then SNG but because of the nature of the delivery and level of dosage, T is likely to have a higher pricing point.

Stage of trial in relation to SNG and number of treated patients should see quicker global approval and distribution if trials are successful.

Let’s hope their is a new successful treatment in the fight against COVID19 as well as ARDS

In this article, but need to subscribe to read the comment.

https://www.kauppalehti.fi/uutiset/koronalaakkeen-kehittajissa-taas-uusi-kurssiraketti-laake-perustuu-samaan-aineeseen-kuin-suomalaisen-faronin-traumakine/72870e04-2f3c-4aa5-a585-c104aa444a4e?ref=twitter:9fc4

Their has to be a read across to FARN today surely. Big sentiment shift

A study with less than 100 patients, 90 in this case carries very little merit and also gives little indication as to the spread of the virus over the UK to consider future planning.

For a company that is already cashed up, would a less dilution through an undersubscribed placing be a bad thing? Not in my book?

I invested due to the revenue generation from its core business and now covid related products.

Sentiment can change on a dime and any news related to CE approval or sales orders can send this the other way and fast.

A fully diluted ODX would have a £71m market cap at 40p, based on what the market currently knows before they attain the next important milestones, imo, this is around fair value but due a bounce from close to an oversold position

Sentiment will return and the book will get stronger once the II’s have rebalanced. It’s in their interest to keep some powder dry to provide liquidity when sentiment changes, as the forthcoming news is the big one.

120 days of slam dunk buckle up government promoted hype.

Yes this does sound like a ramp but can you imagine the journey that is to start from this month. UK-RTC is a company maker in itself. Let alone its core business and additional 4 tests that are to come to market.

Many may find it difficult to sit on a paper loss or get bored with such a period of consolidation in the 40/50’s, but what has been evident is the shear interest and daily transaction volume on the slightest whisper of progress.

I have no doubt that the market need a derisking event such as design freeze, CE approval, validation/verification and corporate sales to take this to the next level. But believe me it’s coming.